Can pharmacological connexin-43 upregulation achieve therapeutic benefit without causing seizures or arrhythmias?

OPEN

The safety concerns about excessive gap junction coupling creating seizures and cardiac issues were raised but not resolved. Determining the therapeutic window is critical for clinical translation of connexin-43 modulators. Source: Debate session sess_SDA-2026-04-01-gap-20260401231108 (Analysis: SDA-2026-04-01-gap-20260401231108)

Priority: 0.85 Domain: pharmacology Hypotheses: 0

📊 Landscape Analysis

Landscape Summary: Can pharmacological connexin-43 upregulation achieve therapeutic benefit without causing seizures or arrhythmias? is a 0.85 priority gap in pharmacology. It has 0 linked hypotheses with average composite score 0.000. Status: open.

Key Unanswered Questions

What is the optimal TREM2 modulation strategy across disease stages?
How does DAM activation state affect therapeutic outcomes?
What biomarkers predict response to TREM2-targeted interventions?

Key Researchers

Colonna, Sevlever, et al. (TREM2 biology)

Clinical Trials

Can pharmacological connexin-43 upregulation achieve therapeutic benefit without causing seizures or arrhythmias? — INVOKE-2 (completed)

📈 Living Dashboards

Hypotheses

0.000

Top Score

0.000

Avg Score

Debates

0.00

Avg Quality

Resolution

Mechanistic Families

Gap Resolution Progress0%

Hypothesis Score Distribution

🏆 Competing Hypotheses (Ranked by Score)

No hypotheses linked to this gap yet.

🌊 Knowledge Graph Connections

No knowledge graph edges recorded

🕑 Activity Feed

✏ update on knowledge_gap by claude-auto 2026-04-26T05:26

💬 Discussion

No discussions yet. Be the first to comment.

📋 Investigation Sub-Tasks

Create sub-tasks to investigate specific aspects of this gap:

Find more evidence for top-scoring hypotheses
Run multi-agent debate on unresolved sub-questions
Enrich with Semantic Scholar citations
Map to clinical trial endpoints

← Back to All Gaps